AnatomyOrganismsDiseasesChemicals and DrugsAnalytical, Diagnostic and Therapeutic Techniques and EquipmentPhenomena and ProcessesDisciplines and OccupationsInformation ScienceHealth Care
Antibodies, MonoclonalProtein EngineeringAntibody SpecificityAntibodiesEpitopesAntibodies, ViralAntibodies, BacterialFluorescent Antibody TechniqueHybridomasCross ReactionsAntibodies, NeutralizingAntibody AffinityMice, Inbred BALB CBinding Sites, AntibodyAntibody FormationMolecular Sequence DataEpitope MappingEnzyme-Linked Immunosorbent AssayAntibodies, Anti-IdiotypicAntigens, SurfaceNeutralization TestsAmino Acid SequenceAntibodies, NeoplasmImmunoglobulin Fab FragmentsImmunoglobulin GImmunoenzyme TechniquesAntibodies, Monoclonal, HumanizedAntigen-Antibody ReactionsCell LineAntigens, NeoplasmMolecular WeightHIV AntibodiesAntigen-Antibody ComplexImmunoglobulin MImmunohistochemistryElectrophoresis, Polyacrylamide GelBlotting, WesternAntibodies, ProtozoanImmunization, PassiveRecombinant ProteinsAntigens, BacterialRabbitsFlow CytometryImmunosorbent TechniquesAntigens, ViralAntibodies, AntinuclearBinding, CompetitiveT-LymphocytesAntibodies, FungalRadioimmunoassayCells, CulturedAntigensGlycoproteinsImmunoblottingAutoantibodiesImmunoassayB-LymphocytesTherapeuticsAntibodies, Monoclonal, Murine-DerivedBase SequenceImmunologic TechniquesTissue DistributionAntigens, CDIodine RadioisotopesRadioimmunodetectionRadioimmunotherapyImmunotoxinsSingle-Chain AntibodiesTumor Cells, CulturedAntibodies, BispecificSpecies SpecificityPeptide FragmentsFluorescent Antibody Technique, IndirectImmunoglobulin IdiotypesAntibodies, BlockingNeoplasmsImmunoglobulin FragmentsChromatography, AffinityAntibody-Dependent Cell CytotoxicityImmunotherapyCattleMembrane GlycoproteinsImmune SeraImmunizationImmunoglobulin Variable RegionProtein BindingPeptidesKineticsPeptide LibraryRecombinant Fusion ProteinsMice, NudeViral Envelope ProteinsPrecipitin TestsCell Line, TumorImmunochemistryMice, Inbred C57BLIndium RadioisotopesAntibodies, HeterophileAntineoplastic AgentsProtein Conformation
MAbSDrug conjugates2023Fully human monoclonalTherapiesInhibitorsTherapeutic antibodiesEfficacyVaccinesTargetsProteinsBiopharmaceutical company focusedAntigenRemdesivirCasirivimabTherapeuticallyHigh-affinityHuman antibodyEffective therapeuticsRecombinantImmune systemTumorsCytotoxicAutoimmuneOncology2021AssaysCloneProteinMedicationsReduction in neutralizationProprietaryNasdaqHybridoma technologySpecificityGuidanceTherapyRapidlyAntigensCancerAcquisitionBroadlyMammalianClinicalBiotechnologyAdvancesPrevention
MAbS10
  • The therapeutic landscape has witnessed a transformative shift with the dominating presence of monoclonal antibodies (mAbs). (reportlinker.com)
  • The biopharmaceutical industry is entering an era dominated by sophisticated therapeutics, and Bi-Specific Monoclonal Antibodies (MAbS) represent a cutting edge development in this sphere. (reportlinker.com)
  • Here we report two monoclonal antibodies (mAbs) cloned from memory B cells of patients recently recovered from COVID-19, and both mAbs specifically bind to the spike (S) protein of SARS-CoV-2, block the binding of receptor binding domain (RBD) of SARS-CoV-2 to human angiotensin converting enzyme 2 (hACE2), and effectively neutralize S protein-pseudotyped virus infection. (medrxiv.org)
  • With the recent acquisition of the technology created by BioClonetics Immunotherapeutics, Inc., the Company has additional and complementary technology for producing fully human monoclonal antibodies (mAbs) that neutralize the HIV virus. (advfn.com)
  • On the newest podcast with Drug Target Review ( Episode 6 - mAbs and SARS-CoV-2 with Dr. Carter Mitchell & Dr. Sharath Madasu, Kemp Proteins ), Carter Mitchell, Chief Scientific Officer and Sharath Madasu, Manager of Protein Characterization of Kemp Proteins , discussed the role of monoclonal antibodies (mAbs) against COVID-19 and how the pandemic has shaped their discovery and development. (moleculardevices.com)
  • Monoclonal antibodies (mAbs) act on viruses through viral neutralization. (moleculardevices.com)
  • They examined monoclonal antibodies, or mAbs, which are proteins that bind to antigens -- foreign substances that enter the body and cause the immune system to mount a protective response. (sciencedaily.com)
  • Manaolana Oncology seeks to build upon the innovative antibody production capabilities and intellectual property of MD Anderson to research and develop novel monoclonal antibodies (mAbs) and other antibody-based therapies for a variety of cancer types, with the goal of advancing promising therapies into clinical studies at MD Anderson. (news-medical.net)
  • Kevin McBride, Ph.D., associate professor of Epigenetics and Molecular Carcinogenesis at MD Anderson, has pioneered a high-throughput platform to clone and produce mAbs from isolated B cells, enabling the development of highly specific antibodies against a particular cell surface target to create novel therapeutic mAbs. (news-medical.net)
  • Therapeutic monoclonal antibodies (MAbs) have been found to be highly effective agents in the treatment of immunological disorders with a high level of success due to their structural specificity and low toxicity. (lu.se)
Drug conjugates3
  • Mersana Therapeutics (NASDAQ: MRSN) is a clinical-stage biopharmaceutical company focused on developing antibody-drug conjugates. (cbinsights.com)
  • Data to be presented include studies on the significant reduction in tumor burden and enhanced survival following Cynviloq intraperitoneal therapy, compared to albumin-bound paclitaxel* intravenous therapy in a metastatic model of ovarian cancer, successful development of anti-cancer antibody drug conjugates using novel C- and K-lock linker technology, and significant efficacy of its c-Met/EGFR Bispecific Targeting ADC in a non-small cell lung cancer model. (prnewswire.com)
  • Antibody-drug conjugates (ADCs) are a new class of targeted anti-cancer therapies that combine a monoclonal tumor-surface-receptor-targeting antibody with a highly cytotoxic molecule payload bonded through specifically designed cleavable or non-cleavable chemical linkers. (bvsalud.org)
20233
  • Five years from now, if a new type of variant comes out, we might be able to use a monoclonal antibody raised against the wild type PLUS one that came out in 2023 as a combination therapy to have more efficacy against that particular variant. (moleculardevices.com)
  • February 15, 2023 - Trial protocol may be adapted to evaluate additional therapeutics. (nih.gov)
  • WHO Therapeutics and COVID-19: Living guideline, 13 January 2023, page 12. (who.int)
Fully human monoclonal1
  • Abelacimab is a novel, highly selective, fully human monoclonal antibody with dual inhibitory activity against factor XI and its active form, factor XIa. (medscape.com)
Therapies9
  • . Precision Cancer Therapeutics, 2022 focuses on the expanding area of precision cancer therapies and includes current products available and discusses some of the most exciting developments in progress. (kaloramainformation.com)
  • The University of Texas MD Anderson Cancer Center and Panacea Venture today announced the launch of Manaolana Oncology Inc., a new company created to develop and advance antibody-based therapies against novel cancer antigens. (news-medical.net)
  • Monoclonal antibody therapies have emerged as important treatment options for many types of cancer. (news-medical.net)
  • By combing through petabytes of proteomic data, our team has uncovered many cancer-restricted antigens that may offer prime targets for monoclonal antibody therapies,' Hanash said. (news-medical.net)
  • What monoclonal antibody therapies are available for prevention or treatment of COVID-19 disease? (hematology.org)
  • Initial clinical trials of monoclonal antibody therapies in hospitalized patients with severe COVID-19 disease were stopped due to futility, with no evidence of benefit in preventing ICU admission or death, or other critical disease endpoints. (hematology.org)
  • A database of information provided by manufacturers, regulators, and academics on the activity of both vaccines and antibody therapies against variants is updated daily by the National Institutes of Health (NIH) . (hematology.org)
  • In what settings should treatment with monoclonal antibody therapies be considered for immunocompromised or other hematology patients? (hematology.org)
  • Both of these sublineages contain a mutation (K444T) in the spike protein that confers resistance to the monoclonal antibody bebtelovimab [2], which was previously authorized as one of the second-line therapies to treat COVID-19. (cdc.gov)
Inhibitors3
  • Currently, the prognosis of patients who became refractory to triple-class agents including proteasome inhibitors, immunomodulatory drugs, and anti-CD38 antibodies is extremely poor. (bvsalud.org)
  • References Patients receiving drugs in the novel class of cancer therapeutics called immune checkpoint inhibitors, have an increased risk for development of autoimmune disorders, including endocrine disorders. (msdmanuals.com)
  • Cancer therapy based on recombinant antibodies against tumor associated target molecules or checkpoint inhibitors have resulted in a number of clinical trials, aiming at improved treatment options for the patients. (lu.se)
Therapeutic antibodies3
  • Biopharmaceuticals, particularly therapeutic antibodies, are revolutionizing modern medical treatments due to their targeted approach and ability to harness the body's own immune responses. (reportlinker.com)
  • The growth in terms of therapeutic antibodies demand, increasing utilization of separation & purifying techniques in the food industry, and emerging R&D activities in biopharmaceutical are the some of the factors contributing to the chromatography resins industry growth. (prnewswire.co.uk)
  • Vetmab Bio's approach to mAb development is based on its proprietary antibody discovery platform, which enables the rapid identification and optimization of novel therapeutic antibodies with high affinity and specificity for their targets. (connect.org)
Efficacy4
  • For instance, although most Emergency Use Authorized antibodies work on the Alpha and the Delta Variants, they exhibit a lower efficacy in the Omicron Variant. (moleculardevices.com)
  • he get the 85% efficacy claim for therapeutics such as Remdesivir and monoclonal antibodies? (democraticunderground.com)
  • Roche reports that this technology will enable it to generate monoclonal and polyclonal antibody therapeutics with enhanced efficacy. (genengnews.com)
  • However, with the evolution of viral spike protein mutant strains, particularly Omicron, the majority of available single or even double monoclonal antibody preparations have shown reduced neutralizing activity in the laboratory and are presumed less effective for prevention or protection against disease progression, although clinical studies documenting breakthrough infections or loss of efficacy are lacking . (hematology.org)
Vaccines3
  • Through mRNA administration, vaccines prompt your cells to produce a harmless version of the spike protein, thereby stimulating your immune system to produce antibodies to fight off the potential threat. (moleculardevices.com)
  • We particularly monitor for sub-lineages that could impact therapeutics, such as monoclonal antibodies and vaccines. (whitehouse.gov)
  • At this time, there is no evidence that the sub-lineage AY 4.2 impacts the effectiveness of our current vaccines or therapeutics, and we will continue to follow up. (whitehouse.gov)
Targets1
  • A monoclonal antibody targets human proteins rather than attacking the virus directly. (actgnetwork.org)
Proteins3
  • There are also fusion proteins mimicking the variable domains of two antibodies. (wikipedia.org)
  • The major antibody class found in the blood, IgG, has a remarkable persistence, with a serum half-life of 20-23 days, compared with only hours or a few days for other circulating proteins 5 . (nature.com)
  • The selected biomarkers are defined with antibodies directed against cancer associated markers released by the tumor (the secretome) or immuno regulatory proteins, as part of a systematic response. (lu.se)
Biopharmaceutical company focused1
  • Vetmab Biosciences is a veterinary biopharmaceutical company focused on developing best in class monoclonal antibody ("mAb") therapeutics for dogs and cats. (connect.org)
Antigen6
  • A bispecific monoclonal antibody (BsMAb, BsAb) is an artificial protein that can simultaneously bind to two different types of antigen or two different epitopes on the same antigen. (wikipedia.org)
  • Naturally occurring antibodies typically only target one antigen. (wikipedia.org)
  • The furthest developed of these newer formats are the bi-specific T-cell engagers (BiTEs), which uses the G4S linker to connect two ScFvs-one CD3 antibody ScFv and one tumor-associated antigen (TAA) or tumor-specific ScFv-to redirect T cells to cancer cells for target killing. (wikipedia.org)
  • The current landscape of novel therapeutics, specifically focused on carcinoembryonic antigen (CEA) related drugs in development, is rapidly evolving. (reportlinker.com)
  • avenue of research has been the development of protein-based "point-of-care" diagnostic assays for antigen and antibody detection. (who.int)
  • Autoimmune Disorders In autoimmune disorders, the immune system produces antibodies to an endogenous antigen (autoantigen). (msdmanuals.com)
Remdesivir1
  • Antiviral therapeutics for the treatment of COVID-19 , ritonavir-boosted nirmatrelvir (Paxlovid™) , remdesivir (Veklury®) , and molnupiravir (Lagevrio™) , retain activity against currently circulating Omicron sublineages. (cdc.gov)
Casirivimab2
  • The new recommendation is regarding the use of a combination of neutralizing monoclonal antibodies, casirivimab and imdevimab in the treatment of non-severe patients at highest risk of hospitalization, and those with severe infection and are critically ill. (who.int)
  • The Omicron variant, with its numerous mutations in the spike protein, is not neutralized by bamlanivimab and etesevimab or casirivimab and imdevimab, th e most frequently prescribed monoclonal antibody- based COVID-19 treatments (4-5). (cdc.gov)
Therapeutically3
  • Combinations of antibodies fully protected mice challenged with vaccinia virus and were also active therapeutically. (who.int)
  • A research team has discovered important details about how therapeutically relevant human monoclonal antibodies can protect against Crimean Congo Hemorrhagic Fever virus. (sciencedaily.com)
  • Combinations of monoclonal antibodies used therapeutically to modulate the IMMUNE SYSTEM. (bvsalud.org)
High-affinity1
  • In Phase I, high-affinity T-2 neutralizing human antibodies will be developed and validated using an in vitrosystem. (sbir.gov)
Human antibody2
  • The CAR.TNK technology platform combines Conkwest's proprietary Neukoplast cell line with Sorrento's proprietary G-MAB® fully human antibody technology and CAR designs to further enhance the potency and targeting of Neukoplast. (prnewswire.com)
  • A California-based company with a subsidiary in Germany, THP is focused on research in human antibody technologies. (genengnews.com)
Effective therapeutics2
  • We would like to know more about its mechanism of action so that specific and effective therapeutics can be developed. (sciencedaily.com)
  • I look forward to working with Gennao Bio on the continued development of the GMAB platform to develop effective therapeutics for the treatment of oncology indications, as well as monogenic skeletal and cardiac muscle diseases. (biospace.com)
Recombinant1
  • The Company is in the final development of the recombinant of the parent antibody (identified as "Clone 3"), which has been shown in in vitro tests conduction in 5 international laboratories to fully neutralized over 95% of all strains and viral subtypes of HIV-1 against which it was tested. (advfn.com)
Immune system2
  • Antibodies that develop naturally against HIV recognize and attach to one part of the virus so that the body's immune system can try to attack it. (actgnetwork.org)
  • Antibodies are usually made by a person's own immune system, but they can also be manufactured as a drug. (actgnetwork.org)
Tumors1
  • This antibody, a modified version of 3E10, forms non-covalent complexes with RNAs and can mediate highly specific delivery broadly into tumors via intravenous injection by targeting the nucleoside transporter ENT2. (biospace.com)
Cytotoxic3
  • Catumaxomab, one of the first trifunctional antibodies approved for therapeutic use, binds both CD3 on cytotoxic T cells and EpCAM on human adenocarcinomas. (wikipedia.org)
  • BACKGROUND: SGN-B7H4V is a novel investigational vedotin antibody-drug conjugate (ADC) comprising a B7-H4-directed human monoclonal antibody conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) via a protease-cleavable maleimidocaproyl valine citrulline (mc-vc) linker. (bvsalud.org)
  • Monoclonal antibodies Systemic cancer therapy includes chemotherapy (ie, conventional or cytotoxic chemotherapy), hormone therapy, targeted therapy, and immune therapy (see also Overview of Cancer Therapy). (msdmanuals.com)
Autoimmune1
  • Several factors, including rising cases of autoimmune diseases, lifestyle changes, and healthcare advancements, spark a growing demand for Antinuclear Antibody (ANA) Screenings. (reportlinker.com)
Oncology3
  • Manaolana Oncology brings together MD Anderson's expert scientists and clinicians with Panacea's experienced biotechnology team to create a focused organization working to develop a novel portfolio of monoclonal antibodies. (news-medical.net)
  • We look forward to collaborating with Manaolana Oncology to develop novel antibody-based therapeutics that offer patients impactful new treatment options. (news-medical.net)
  • Manaolana Oncology intends to optimize the techniques developed at MD Anderson in order to improve the speed and efficiency in of producing antibodies against promising candidate antigens. (news-medical.net)
20212
  • On December 17, 2021, Vera Therapeutics, Inc. (Nasdaq: VERA), a clinical-stage biotechnology company focused on developing treatments for immunological diseases that improve patients' lives, announced that it has acquired MAU868, a first-in-class monoclonal antibody to treat BK virus (BKV) infections, and has entered into a credit facility with Oxford Finance LLC (Oxford) to provide borrowing capacity up to $50 million. (bioquicknews.com)
  • NEW HAVEN, Conn., April 10, 2021 (GLOBE NEWSWIRE) -- Gennao Bio , a privately-held genetic medicines company developing first-in-class, targeted nucleic acid therapeutics, today announced a late-breaking poster detailing preclinical results for its proprietary, non-viral gene monoclonal antibody (GMAB) nucleic acid delivery system. (biospace.com)
Assays2
  • The antibody is tested and validated for WB, ICC/IF assays with the following recommended dilutions: WB (1:1000), IHC (1:1000), ICC/IF (1:100). (exoquick.com)
  • The increasing prevalence of neurodegenerative diseases and the mounting demand for effective therapeutic options propel interest in the neuroscience antibodies and assays segment. (reportlinker.com)
Clone2
  • Description: A monoclonal antibody from clone S323A-31 against Rat SUR1 and SUR2B. (exoquick.com)
  • Antibodies produced by a single clone of cells. (curehunter.com)
Protein4
  • The aim of this conference, arranged by Marcus Evans, was to exchange ideas, current research and findings in protein formulation to aid the preparation of final stage therapeutics, for the general market. (soci.org)
  • Biopharmaceutical formulation is an important topic, as more and more protein-based therapeutics such as monoclonal antibodies are reaching the marketplace. (soci.org)
  • Multiple engineered monoclonal antibodies directed against the SARS-CoV-2 spike protein have been developed and tested. (hematology.org)
  • In formulation of protein therapeutics, one of the main concerns is the physical stability of the drug molecule. (lu.se)
Medications1
Reduction in neutralization1
  • 5 Other known attributes of the variant include moderate reduction in neutralization by monoclonal antibody therapeutics, convalescent sera, and post-vaccination sera. (health.mil)
Proprietary3
  • The company has made significant advances in developing human monoclonal antibodies, complemented by comprehensive and fully integrated bispecific antibody and antibody drug conjugate (ADC) platforms that include proprietary conjugation chemistries, linkers and toxic payloads. (prnewswire.com)
  • The GMAB technology platform, exclusively licensed from Yale University, utilizes a proprietary, cell-penetrating antibody to non-covalently bind to and deliver therapeutic levels of multiple types of nucleic acids, including synthetic RNA (ribonucleic acid) messenger RNA, small interfering RNA, deoxyribonucleic acids, antisense oligonucleotides and gene editing molecules. (biospace.com)
  • Gennao Bio is a privately-held genetic medicines company developing first-in-class targeted nucleic acid therapeutics utilizing its proprietary gene monoclonal antibody (GMAB) platform technology. (biospace.com)
Nasdaq4
Hybridoma technology1
  • In 1975, the problem of producing pure antibodies was solved by the creation of hybridoma technology, and the new era of monoclonal antibodies (MoAbs) came. (wikipedia.org)
Specificity1
  • Today, the pilot platform includes up to 500 antibodies and well-conceived bioinformatics has been developed for selection of the orthogonal markers generating the optimal signature for maximum specificity and sensitivity for a particular diagnosis. (lu.se)
Guidance2
  • Living guidance Therapeutics and COVID- biological medical products. (who.int)
  • This HAN Health Update provides health care professionals, public health officials, and the public with guidance on improving use of therapeutics for treatment of COVID-19 and strategies to prevent serious outcomes of COVID-19. (cdc.gov)
Therapy2
  • Madasu further explains: "With the convalescent plasma therapy, A) you are expecting that the donor is still producing neutralizing antibodies, and B) Donor is producing sufficient amounts to be effective at all. (moleculardevices.com)
  • CoV-2 monoclonal antibody-based therapy (7). (cdc.gov)
Rapidly3
  • The lack of binding of mIgG to hFcRn explains why murine antibodies are rapidly removed from the circulation in humans, despite long half-life in mice 32 . (nature.com)
  • Monoclonal antibodies therapeutics are rapidly capturing importance with rise in critical diseases across the world. (prnewswire.co.uk)
  • The advent of the Omicron variant is changing the landscape of therapeutics rapidly, and we recommend checking the National Institutes of Health website for updated information. (hematology.org)
Antigens3
  • This format retains the traditional monoclonal antibody (mAb) structure of two Fab arms and one Fc region, except the two Fab sites bind different antigens. (wikipedia.org)
  • The TandAb platform is formed by a tetravalent antibody molecule containing two binding sites for each of two antigens. (wikipedia.org)
  • Since this is a non-animal system, the platform can generate human antibodies against toxins, pathogens, self-antigens, and the likewhich are by nature difficult to obtain. (sbir.gov)
Cancer3
Acquisition1
  • The company reports that the acquisition strengthens its expertise in therapeutic antibody research. (genengnews.com)
Broadly1
  • The first study of a broadly neutralizing antibody called SAR441236 in humans, will determine if an infusion is safe and tolerable and will measure the amount of SAR441236 in the blood over time. (actgnetwork.org)
Mammalian3
  • Selected clones will beused to generate high-yield producer stable mammalian cell lines for antibody production in large quantity. (sbir.gov)
  • Therapeutic Human Polyclonals developed a transgenic mammalian platform that enhances the generation of monoclonal and polyclonal antibody therapeutics. (genengnews.com)
  • The company has developed a transgenic mammalian platform to create human antibodies. (genengnews.com)
Clinical3
  • Ribon Therapeutics operates as a clinical-stage biotechnology company. (cbinsights.com)
  • Quisovalimab is under clinical development by Avalo Therapeutics and currently in Phase II for Crohn's Disease (Regional Enteritis). (pharmaceutical-technology.com)
  • This lack of benefit is not surprising given that passive antibody administration is unlikely to improve clinical status in most patients already making their own anti-COVID antibodies a week or more after infection. (hematology.org)
Biotechnology1
Advances1
  • Advances in genomics, coupled with the technological amplitude of antibody-based approaches, are strengthening the foundation of this niche market. (reportlinker.com)
Prevention3
  • They talked of revolutionizing drug development and disease prevention through the power of AI and monoclonal antibody technology. (advfn.com)
  • Dan Bloomfield, MD, chief medical officer of Anthos Therapeutics, said that, "Abelacimab embodies its promise as a hemostasis-sparing anticoagulant and represents a paradigm shift in the prevention of stroke and other thrombotic conditions. (medscape.com)
  • The recent increases in the case and hospitalization rates highlight the importance of preventing severe illness through the use of prevention measures and therapeutics. (cdc.gov)